Precigen (I5X) Stock Overview
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
I5X Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.66 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$0.68 |
| Beta | 1.16 |
| 1 Month Change | 15.16% |
| 3 Month Change | 26.71% |
| 1 Year Change | 427.29% |
| 3 Year Change | 182.67% |
| 5 Year Change | -54.23% |
| Change since IPO | -76.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| I5X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.3% | 1.7% | 0.1% |
| 1Y | 427.3% | -30.9% | 13.5% |
Return vs Industry: I5X exceeded the German Biotechs industry which returned -30.9% over the past year.
Return vs Market: I5X exceeded the German Market which returned 13.5% over the past year.
Price Volatility
| I5X volatility | |
|---|---|
| I5X Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I5X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I5X's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Helen Sabzevari | precigen.com |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Precigen, Inc. Fundamentals Summary
| I5X fundamental statistics | |
|---|---|
| Market cap | €1.25b |
| Earnings (TTM) | -€361.69m |
| Revenue (TTM) | €5.36m |
Is I5X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I5X income statement (TTM) | |
|---|---|
| Revenue | US$6.31m |
| Cost of Revenue | US$50.50m |
| Gross Profit | -US$44.19m |
| Other Expenses | US$381.68m |
| Earnings | -US$425.87m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | -700.40% |
| Net Profit Margin | -6,750.13% |
| Debt/Equity Ratio | 221.9% |
How did I5X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/27 19:17 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |